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Introduction
• Periprosthetic joint infections increase 
morbidity and mortality after hip and knee 
arthroplasty1,2,3,4
– Revision arthroplasty and failure post revision
• Emergent problem that requires a clinical 
diagnosis
– Introduction of MSIS criteria in 20115
Introduction
• Increasing development of biomarkers as 
diagnostic tests
– Synovial fluid alpha-defensin
• Incorporated into 2018 MSIS update6
• Prior literature has shown up to 100% for 
specificity and sensitivity7,8,9,10
• Synovial alpha-defensin biomarker 
incorporated into our practice in 2014
Objectives
& Hypothesis
• The purpose of this study was to evaluate our 
implementation of synovial alpha-defensin (Synovasure®) 
with comparison to the 2011 MSIS criteria for diagnosing 
periprosthetic joint infections after hip and knee arthroplasty
• We hypothesized that the sensitivity and specificity of the 
synovial alpha-defensin immunoassay will both be 100%
Approach & Results
• Single center, retrospective chart from 2014 – 2016
• 128 consecutive that came in for evaluation of potential 
hip / knee periprosthetic joint infection (PJI)
• All patients must have received synovial alpha-defensin 
immunoassay in addition to our standard PJI workup
• Data was collected from electronic medical records after 
IRB approval
• Rationale - Evaluate the potential diagnostic capability of 
synovial-alpha defensin
Approach & Results
• 28 patients had a positive synovial alpha defensin 
test vs. 100 patients with a negative test
– There were no significant differences in 
demographics between groups
Age 69.5 67.2 0.381
Sex (M/F) 18/10 48/52 0.140
Hip / Knee 10/18 52/48 0.127
Tobacco Use 4 12 0.750
Diabetes 8 23 0.619
Approach & Results
• Results of our standard PJI workup:
CRP Serum 112.4 20.9
Synovial WBC 42,723.5 739.3
Synovial PMN 87.2% 41.2%
Positive Culture 5 (17.9%) 7 (7%)
Gram Stain 8 (28.6%) 0
Crystals 9 (32.1%) 0
Approach & Results
• In comparison to 2011 MSIS as gold standard
Sensitivity 95.00% 75.13 – 99.87%
Specificity 91.67% 84.77 – 96.12%
Positive Predictive Value 67.86% 52.84 – 79.91%
Negative Predictive Value 99.00% 93.61 - 99.85%
Accuracy 92.19% 86.10 – 96.19%
Conclusions
• Our results demonstrated that there is a role for synovial-
alpha defensin immunoassay in PJI workup
• However there was a low positive predictive value and a 
failure to achieve 100% in either sensitivity or specificity 
– Therefore it cannot be used as a standalone test
• Our findings support more recent literature of 
incorporating biomarkers into the clinical picture
– 2018 MSIS criteria 
• Analysis of our results has kept Synovasure ® as part of 
our standard PJI workup
Future Directions
• Since the implementation of this study, 
potential sample size has grown 
– Possibility of re-evaluating with most up-to-date 
population
– Possibility of utilizing the 2018 MSIS criteria for 
comparison
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